



# Checkpoint inhibitors and myeloma: promises, deadlocks and new directions

Luca Bertamini, Francesca Gay

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

*Correspondence to:* Dr. Francesca Gay, MD, PhD. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3 -10126 Torino, Italy. Email: fgay@cittadellasalute.to.it.

*Provenance and Peer Review:* This article was commissioned by the editorial office, *Annals of Translational Medicine*. The article did not undergo external peer review.

*Comment on:* Mateos MV, Blacklock H, Schjesvold F, *et al.* Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. *Lancet Haematol* 2019;6:e459-69.

Submitted Jan 02, 2020. Accepted for publication Feb 06, 2020.

doi: 10.21037/atm.2020.02.65

**View this article at:** <http://dx.doi.org/10.21037/atm.2020.02.65>

In the last decades, immune-checkpoint inhibitors have markedly improved the survival outcomes of many solid tumors (1). Multiple myeloma (MM) is a hematologic malignancy, in which there is strong evidence of the role of an altered immune system in the pathogenesis of the tumor. This hypothesis was corroborated by the efficacy of some drugs that target the immune environments, such as the immunomodulatory drugs (IMiDs) (2-4). High expression of PD-L1 (one of the ligands of the immune checkpoint receptor PD-1) on MM neoplastic cells and other bone marrow microenvironment cells added a biological rationale of its use (5,6). In the preclinical setting, the addition of an IMiD to PD-1/PD-L1 inhibitors increased tumor cell death (4,7).

Pembrolizumab is an anti-PD-1 humanized IgG4k monoclonal antibody (mAb) that showed a promising response rate in early phase I and I/II clinical trials in combination with backbone therapies against MM, namely lenalidomide and dexamethasone (Rd) and pomalidomide and dexamethasone (Pd) (8). Badros *et al.* reported an overall response rate (ORR) of 60%, a median progression-free survival (PFS) of 17.4 months and an overall survival (OS) not reached (NR) with pembrolizumab in combination with Pd (Pembro-Pd) in 48 heavily pretreated relapsed and/or refractory (RR) MM patients (9). In another phase I study combining pembrolizumab with Rd (Pembro-Rd), ORR was 44%, median PFS 7.2 months and 2-year OS 65%. In these two trials toxicities were similar, with 16%

and 13% of patients who experienced immune-related adverse events (iRAEs; *Table 1*).

Based on these phase I and I/II studies, 2 phase III trials were designed. The KEYNOTE-183 randomized RRMM patients to Pembro-Pd *vs.* Pd and the KEYNOTE-185 compared Pembro-Rd *vs.* Rd for newly diagnosed (ND)MM patients not eligible for transplant (NTE). The treatment schedules were similar, with pembrolizumab at 200 mg every 3 weeks as continuous therapy combined either with backbone Pd for RRMM patients (KEYNOTE-183) or with Rd for NTE NDMM patients (KEYNOTE-185). In the KEYNOTE-183, pomalidomide was administered at 4 mg daily on days 1–21 and dexamethasone at 40 mg (20 mg for elderly patients >75 years old) on days 1, 8, 15, and 22 of 28-day cycles. In the KEYNOTE-185, lenalidomide was administered at 25 mg daily on days 1–21 and dexamethasone at 40 mg daily on days 1, 8, 15, and 22 of 28-day cycles. The primary endpoints were PFS in the KEYNOTE-185 and PFS and OS in the KEYNOTE-183. The good results of phase I/II studies and the results in solid tumors raised high expectations. Nevertheless, both studies were stopped by the Food and Drug Administration (FDA) before completing the enrollment, since an interim analysis revealed an increased risk of death in the pembrolizumab arms (hazard ratio [HR] for OS 1.61 and 2.06 in the KEYNOTE-183 and KEYNOTE-185, respectively; P value = NS for both) (10,11).

At the time of the interim analysis of the

**Table 1** Pembrolizumab for the treatment of multiple myeloma: selected clinical trials

Reference	HP-00061522 [Badros <i>et al.</i> 2017] (9)	KEYNOTE-023 (8)	KEYNOTE-183 (10)	KEYNOTE-185 (11)	Pro2016-0262 (12)
ClinicalTrials.gov ID	NCT02289222	NCT02036502	NCT02576977	NCT02579863	NCT02906332
Treatment	Pembro-Pd	Pembro-Rd	Pembro-Pd vs. Pd	Pembro-Rd vs. Rd	Pembro-Rd after ASCT
Phase	I/II	I	III	III	II
Population	RRMM	RRMM	RRMM	NTE NDMM	TE NDMM HR <sup>s</sup>
N° of Subjects	48	62	249: 125 vs. 124 (planned 300)	301 (planned 640)	12
FU, median (range), mo	15.6 (9.2–17)	18.9 (0.8–36)	8.1 (4.5–10.9)	6.6 (3.4–9.6)	32.2
Performance status (PS)	ECOG 0–1: 46 pts (96%)	ECOG 0: 15 pts (24.2%)	ECOG 0:	ECOG 0:	
	ECOG 2: 2 pts (4%)	ECOG 1: 47 pts (75.8%)	- Pembro-Pd: 60 pts (48%) - Pd: 60 pts (48%)	- Pembro-Rd: 51 pts (34%) - Rd: 55 pts (37%)	
Age, median, years [range]	64 [35–83]	61 [46–77]	65 [60–74]	74 [70–79]	67.2 [63.9–70.2]
Previous therapy lines	Median: 3 (range, 2–5)	- 2 lines: 29% - 3 lines: 16% - 4 lines: 19% ≥5 lines: 33%	Previous recurrence: 3 (1–3)	-	Induction with: - VRd 41% - KRd 33% - Kcyd 16% - VRcyd 8%
Len and/or PI: 48 pts (100%)	Len: 58 pts (93%)	Len: 119 (95%) vs. 116 (94%) pts			
Prior ASCT: 31 pts (72%)	Bort: 61 pts (79%) Carf: 16 pts (26%) Pom: 18 pts (29%)	Bort: 121 (97%) vs. 116 (94%) pts Carf: 34 (27%) vs. 33 (27%) pts Dara: 9 (7%) vs. 8 (6%) pts			
Refractory, n (%)	Len: 43 (90%) PI: 38 (79%)	Prior ASCT: 54 pts (87%) Len: 47 (75%) Double or more refractory: 41 (66%)	Prior ASCT: 77 (62%) vs. 81 (65%) pts Len 107 (86%) Double refractory: 51 (41%) vs. 50 (40%)		
	Len + PI: 35 (73%)	Triple or more refractory: 28 (22%) vs. 31 (25%)			

**Table 1** (continued)

Table 1 (continued)

Reference	HP-00061522 [Badros et al. 2017] (9)	KEYNOTE-023 (8)	KEYNOTE-183 (10)	KEYNOTE-185 (11)	Pro2016-0262 (12)
ISS	NA	ISS I: 35% ISS II: 27% ISS III: 34%	Pembro-Pd: - ISS I: 36% - ISS II: 37% - ISS III: 26%  Pd: - ISS I: 36% - ISS II: 31% - ISS III: 27%	Pembro-Rd: - ISS I: 25% - ISS II: 45% - ISS III: 29%  Rd: - ISS I: 34% - ISS II: 44% - ISS III: 21%	ISS I: 50% ISS III: 33%
High-risk (HR) CAs (%)	30 (62%) <sup>†</sup>	6 (9.7%) <sup>‡</sup>	28 (22%) vs. 17 (14%)	24 (16%) vs. 10 (7%)	del17p: 66% amp1q: 8%
Plasmacytoma, n (%)	NA	NA	15 (12%) vs. 6 (5%)	4 (3%) vs. 11 (7%)	NA
AEs, n (%)	Any grade: 35  ≥G3: 20 (42%), 1 died of AE (febrile neutropenia) irAEs: 16 (33%), 5 G≥3: - autoimmune pneumonia: 6 (1 G3, other G1-2) - hypothyroidism: 5 (10%; 2 G≥3) - adrenal insufficiency: 2 - hepatitis: 2 - vitiligo: 1	Any grade: 62 (100%)  ≥G3: 37 (60%), 2 died of AE (VOD, ischemic stroke) 77 Pd pts (64%) Hematologic ≥G3: - thrombocytopenia: 12 - neutropenia: 22 - anemia: 11 irAEs: 8 (12%) all G1-2	Any grade: 119 (99%) vs. 116 (96%)  G5 in 13 (11%) Pembro-Pd pts vs. 3 Pd pts (2%) irAEs: 21 (18%) all in Pembro arm - 10 G3-4 (8%) - 2 G5 (Stevens-Johnson syndrome and myocarditis) discontinuation rate 20% vs. 8% due to TRAE	Any grade: 140 (94%) vs. 133 (92%)  SAEs: 81 (54%) vs. 57 (39%)  G3-4: 95 (64%) vs. 65 (45%)  G5: - 48 irAEs (31%), - 34 ≥G3 (23%) - 1 G5 (Stevens-Johnson Syndrome) discontinuation rate 21% vs. 8% due to TRAE	Any grade: 90  ≥G3: 5 events - 1 bacterial pneumonia - 1 hypoxia - 1 maculopapular rash - 2 neutropenia
Response	60% ORR	44% ORR	Pembro-Pd: 34% ORR vs. Pd: 40% ORR	Pembro-Rd: 64% ORR vs. Rd: 62% ORR	2-year FU: - 8 sCR (73%) - 2 (18%) CR - 1 (9%) VGPR  11 pts completed therapy, 8 pts were evaluable for MRD, 7 pts were MRD-negative
	6% sCR 19% VGPR 33% PR 23% SD	4% sCR 12% VGPR 28% PR 50% SD			

Table 1 (continued)

Table 1 (continued)

Reference	HP-00061522 [Badros et al. 2017] (9)	KEYNOTE-023 (8)	KEYNOTE-183 (10)	KEYNOTE-185 (11)	Pro2016-0262 (12)
PFS, median (range), mo	17.4 (11.7–18.8)	7.2 (3.9–12.3)	Pembro-Pd: 5.6 (3.7–7.5) vs. Pd: 8.4 (5.9–NR)	Median PFS: NR	Median PFS of 8–14, PFS 91.3% at 1 year after ASCT
In HR cytogenetics: median 15.1 mo				Pembro-Rd PFS at 6 months: 82% vs. Pembro-Rd: PFS: 87%	PFS 65.2% 2-year post-ASCT
OS, median (range), mo	Median NR (18.9–NR)	Median NR	Pembro-Pd: NR (12.9–NR) vs. Pd: 15.2 (12.7–NR)	Median OS: NR	
		1-year survival rate: 82.6%	Deaths: 29 (23%) [16 PD, 13 AEs] vs. 21 (17%) [18 PD 3 AE]	Deaths: 19 (13%) vs. 9 (6%)	
		2-year survival rate: 64.7% a.			

†, high risk was defined by the presence of at least one of the following chromosomal abnormalities (CA): del17p, t(14:16), t(14:20), t(4:14), and/or amp1q; ‡, high risk defined by at least one of the following CA: del17p, t(14:16), and/or t(4:14); §, high risk was defined by the presence of: ISS stage III; del13q by cytogenetics; FISH with 1q amplification, 1p deletion (del), p53 del, t(4:14), t(14:16), t(14:20), hypodiploidy; or a high-risk gene expression profile score. CA, chromosomal abnormalities; Pembro, pembrolizumab; Poma, P, pomalidomide; Dex, d, dexamethasone; Len, R, lenalidomide; ASCT, autologous stem-cell transplantation; RRM, relapsed/refractory multiple myeloma; NDMM, newly diagnosed multiple myeloma; TE, transplant-eligible patients; NTE, non-transplant-eligible patients; ECOG, Eastern Cooperative Oncology Group Performance Status; pt(s), patient(s); PI, proteasome inhibitor; Bort, V, bortezomib; Carf, K, carfilzomib; Dara, daratumumab; Cyclo, Cy, cyclophosphamide; ISS, International Staging System; NA, not available; AEs, adverse events; G, grade; irAEs, immune-related AEs; TRAE, treatment-related AE; SAEs, serious AEs; VOD, veno-occlusive disease; ORR, overall response rate; CR, complete response; sCR, stringent CR; PR, partial response; VGPR, very good PR; SD, stable disease; MRD, minimal residual disease; PFS, progression-free survival; FU, follow-up; mo, months; HR, high risk; OS, overall survival; NR, not reached; y, years; PD, progressive disease; FISH, fluorescence in situ hybridization; del, deletion; amp, amplification; a., appendix.

KEYNOTE-183, 29 patients died in the pembrolizumab group [16 due to progressive disease (PD) and 13 due to AEs] *vs.* 21 in the control group (18 due to PD and 3 due to AEs). Causes of deaths were mainly infections and cardiac events. Of the 13 deaths in the pembrolizumab group, only 4 were considered treatment-related AEs (TRAEs) and 2 were considered iRAEs due to pembrolizumab (Stevens-Johnson syndrome and myocarditis). This study also showed higher rates of serious AEs (SAEs), grade (G) 3–4 AEs and discontinuations due to AEs occurred with Pembro-Pd. In general, G $\geq$ 3 iRAEs occurred with a higher incidence: ~18% of subjects, compared to 10% in the study reported by Badros *et al.*

Similar findings were reported in the KEYNOTE 185, with 19 patients who died in the Pembro-Rd arm (6 due to PD and 13 due to AEs; 6 TRAEs, of which 5 related to pembrolizumab) *vs.* 9 in the Rd arm (1 due to PD and 8 due to AEs). Moreover, increased rates of SAEs, G3–4 AEs and discontinuations due to AEs with Pembro-Rd were observed (*Table 1*).

Both trials failed to show higher ORR or time to progression (TTP)/PFS in the experimental arms. A subsequent FDA analysis on the response of patients who experienced or not iRAEs also did not detect a clear benefit of adding pembrolizumab to backbone therapies, not even in patients who developed iRAEs, who might have been those for whom the drugs should have been more active (12). Although iRAEs due to immune checkpoint inhibition are well known and manageable in most tumors, in those trials they seemed to be more frequent and severe; this should be related to a synergistic effect with IMiDs. Besides, iRAEs were more frequent in NDMM subjects (KEYNOTE-185) than in RRMM subjects (KEYNOTE-183), possibly unveiling a less exhausted immune system.

The efficacy of continuous therapy relies on tolerability. In this context, it is clear that a high rate of discontinuation due to AEs hinders the efficacy of the treatment itself.

Of note, both trials were stopped after a relatively short follow-up (6.6 months for the KEYNOTE-185 and 8.5 for the KEYNOTE-183), since the increased deaths had been reported quite early. Both trials also showed an imbalance in baseline patient characteristics, with a high number of high-risk patients in the pembrolizumab arms, as compared with the control arms (KEYNOTE-183: high-risk cytogenetics 22% *vs.* 14%, extramedullary disease 12% *vs.* 5%; KEYNOTE-185: high-risk cytogenetics 24% *vs.* 10%). Early deaths, and in particular deaths due to infections, are well recognized in MM patients and often

they are not merely related to the treatment per se, but to the immunosuppression induced by the disease itself, particularly in patients at high risk and high tumor burden. In fact, a review of disease characteristics of patients who died in the KEYNOTE-183 showed that high-risk features were more frequently observed in the pembrolizumab group than in the control group. Moreover, a post-hoc analysis looking for strong predictors of death showed that the ECOG performance status (PS) was both prognostic and predictive of outcome (ECOG PS 1 was associated with an increased risk of death: HR 2.3, 95% CI: 1.11–4.76). A similar analysis was performed on the KEYNOTE-185, but it was deemed inconclusive due to the low number of death events [28].

On the basis of the above-mentioned data and focusing on the excess of toxicity as the main reason for the failure of checkpoint inhibitor therapy, we could consider whether these drugs could give better results in a ‘safer’ setting. For instance, these agents could possibly have a role in the consolidation therapy after autologous stem-cell transplantation (ASCT), aiming at achieving a higher rate of minimal residual disease negativity or at sustaining a deep response. In this setting, tolerability may be better because of a better PS. In a phase II trial (NCT02906332), patients received a post-ASCT consolidation with Pembro-Rd, which was given for 2 cycles plus 2 additional cycles without corticosteroid. Twelve patients were treated, with a median follow-up of 32 months. PFS rates were respectively 91.3% and 65.2% at 1 and 2 years after ASCT, with 5% of AEs being of grade >3 (13). However, after the interim analyses of the KEYNOTE-183 and -185 studies, the study was stopped together with all the other studies involving checkpoint inhibitors for the treatment of MM.

One of the possible explanations for the low efficacy and high toxicity of these combinations of immune checkpoint inhibitors and IMiDs could be related to the important level of immunodeficiency in MM patients (10), similarly to what happens with congenital immunodeficiency syndromes, in which the immune response deficit both decreases the activity of the immune system against pathogens and cancer cells and increases the burden of autoimmune disease. Indeed, a deficient immune system is also unable to regulate immune reaction against the ‘self’. In the context of MM, we can hypothesize that the immune system becomes anergic against the tumor and that, at the same time, a deregulated immunity can be boosted by immune checkpoint inhibitors to perform an autoimmune reaction (14,15). Moreover, the use of dexamethasone at

such high doses could also decrease the immune response and induce an anergic microenvironment, which cannot be susceptible to checkpoint inhibition (10). It should be noted that immune checkpoint inhibitors have not been combined with corticosteroids in trials for the treatment of solid or hematologic tumors other than MM.

If we consider that part of the toxicity with pembrolizumab plus IMiDs could be related to a synergistic effect of the two drugs on the immune system, but also that we need to overcome immunosuppression, an alternative should be the use of checkpoint inhibitors in combination with other drug classes, such as the mAbs. Anti-CD38 mAbs are known to have a immunomodulatory activity and to be able to activate the ‘frozen’ immune microenvironment, thus reducing immunosuppression (16).

To conclude, given the great results of immunotherapy for the treatment of MM, such as in the case of IMiDs and CAR T cells (3), checkpoint inhibition did not fulfill the promise envisaged during its early usage. Nevertheless, a further investigation of the exact role of checkpoint inhibition in the complex therapeutic scenario of MM is still a challenge that we have to face.

## Acknowledgments

*Funding:* None.

## Footnote

*Conflicts of Interest:* Both authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/atm.2020.02.65>). FG has received honoraria from Amgen, Celgene, Janssen, Takeda, and Bristol-Myers Squibb; has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, Roche, AbbVie, Adaptive, and Seattle Genetics. LB has no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with

the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443-54.
2. Oliva S, Troia R, D'Agostino M, et al. Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. *Front Immunol* 2018;9:2749.
3. D'Agostino M, Boccadoro M, Smith EL. Novel Immunotherapies for Multiple Myeloma. *Curr Hematol Malig Rep* 2017;12:344-57.
4. Gay F, D'Agostino M, Giaccone L, et al. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. *Clin Lymphoma Myeloma Leuk* 2017;17:471-8.
5. Yousef S, Marvin J, Steinbach M, et al. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. *Blood Cancer J* 2015;5:e285.
6. Ray A, Das DS, Song Y, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. *Leukemia* 2015;29:1441-4.
7. Görgün G, Samur MK, Cowens KB, et al. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. *Clin Cancer Res* 2015;21:4607-18.
8. Mateos MV, Orlowski RZ, Ocio EM, et al. Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. *Br J Haematol* 2019;186:e117-21.
9. Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. *Blood* 2017;130:1189-97.
10. Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. *Lancet Haematol* 2019;6:e459-69.
11. Usmani SZ, Schjesvold F, Oriol A, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a

- randomised, open-label, phase 3 trial. *Lancet Haematol* 2019;6:e448-58.
12. Krauss AC, Mulkey F, Shen YL, et al. FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response. *J Clin Oncol* 2018;36:abstr 8008.
  13. Bansal M, Siegel DS, Ahn J, et al. Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma. *Blood* 2019;134:1911. doi: 10.1182/blood-2019-125155.
  14. Patuzzo G, Barbieri A, Tinazzi E, et al. Autoimmunity and infection in common variable immunodeficiency (CVID). *Autoimmun Rev* 2016;15:877-82.
  15. Schmidt RE, Grimbacher B, Witte T. Autoimmunity and primary immunodeficiency: two sides of the same coin? *Nat Rev Rheumatol* 2017;14:7-18.
  16. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. *Blood* 2016;128:384-94.

**Cite this article as:** Bertamini L, Gay F. Checkpoint inhibitors and myeloma: promises, deadlocks and new directions. *Ann Transl Med* 2020;8(12):777. doi: 10.21037/atm.2020.02.65